TUCSON, Ariz., March 20, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE:PMI) (the "Company"), parent company of SynCardia Systems LLC, maker of the world's first total artificial heart approved by both the U.S. FDA and Health Canada, today announced it will be presenting a poster consisting of new preclinical data related to its next-generation Emperor Total Artificial Heart at the American College of Cardiology (ACC)'s Annual Scientific Session & Expo (ACC.26) to be held in New Orleans, Louisiana from March 28 to March 30, 2026. Abstract Poster Presentation – ACC.26 Title: THE EMPEROR TOTAL ARTIFICIAL HEART: A FULLY IMPLANTABLE, AUTOREGULATING SOLUTION FOR ADVANCED HEART FAILUREDat

TUCSON, Ariz., March 19, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE:PMI) (the "Company"), parent company of SynCardia Systems LLC, maker of the world's first total artificial heart approved by both the U.S. FDA and Health Canada, today highlighted a case reported by UCSF Health in which a patient in his twenties with advanced biventricular heart failure was successfully bridged to heart transplantation using the SynCardia Total Artificial Heart. The patient, a male in his twenties, received the SynCardia Total Artificial Heart on November 15, 2025 to restore full circulatory support while awaiting a donor heart. After 119 days of support with the device, the patient underwent a su

TUCSON, Ariz., March 17, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE:PMI) (the "Company"), parent company of SynCardia Systems LLC, maker of the world's first total artificial heart approved by both the U.S. FDA and Health Canada, today announced that a 29-year-old patient successfully received a donor heart transplant after living for more than four years supported entirely by the SynCardia Total Artificial Heart. The patient was implanted with the SynCardia Total Artificial Heart on September 2, 2021, after developing severe biventricular heart failure. The device replaced the pumping function of both sides of the heart, maintaining circulation while the patient awaited a donor

TUCSON, Ariz., March 13, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE:PMI) (the "Company"), parent company of SynCardia Systems LLC, maker of the world's first total artificial heart approved by both the U.S. FDA and Health Canada, today announced that the SynCardia Total Artificial Heart ("STAH") will be featured in an upcoming segment on BTV Business Television airing on the FOX Business News on Saturday, March 14 at 5:00 p.m. EST. The segment will highlight the Company artificial heart technology designed to replace the pumping function of a failing human heart during the time that a patient awaits transplantation. With more than 2,100 implants performed worldwide, the STAH rem

TUCSON, Ariz., March 12, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE:PMI) (the "Company"), parent company of SynCardia Systems LLC, maker of the world's first total artificial heart approved by both the U.S. FDA and Health Canada, today announced it will host an its Annual Business Update virtual call, which will be webcasted, on Wednesday, March 25, 2026 at 4:30 p.m. EDT, following the filing of the Company's Form 10-K for the fiscal year ended December 31, 2025. The webcast will feature business updates from management, including discussion of the Company's commercial activities and development of its next-generation, fully implantable total artificial heart platform known as Emp

TUCSON, Ariz., March 02, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE:PMI) ("Picard" or the "Company"), parent company of SynCardia Systems LLC, maker of the world's first total artificial heart approved by both the U.S. FDA and Health Canada, today announced that Dr. Andre Simon, Vice President of Clinical Affairs, will deliver three scientific and educational presentations at the Technology and Heart Failure Therapeutics (THT) 2026 conference to be held in Boston from March 2nd to March 4th 2026. Dr. Simon's presentations will focus on both the current SynCardia Total Artificial Heart (STAH) and the Company's next-generation fully implantable Emperor system, reinforcing Picard Med

TUCSON, Ariz., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE:PMI) ("Picard" or the "Company"), parent company of SynCardia Systems LLC, maker of the world's first total artificial heart approved by both the U.S. FDA and Health Canada, today announced it will participate in the inaugural "Hands-On Training Day" at the Technology and Heart Failure Therapeutics (THT) 2026 conference to be held in Boston on March 1st 2026. This interactive, case-based program hosted for the first time at the conference will bring together leading clinicians and innovators to advance education in temporary and durable mechanical circulatory support, hemodynamic monitoring, and the management of

Invitation-only program at Houston Methodist, one of the top heart transplant centers in the U.S., highlights the growing need for SynCardia Total Artificial Heart technology. Training initiative at Houston Methodist is expected to enable expanded adoption of the SynCardia Total Artificial Heart through further education. TUCSON, Ariz., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE:PMI) ("Picard" or the "Company"), parent company of SynCardia Systems LLC, maker of the world's first total artificial heart approved by both the U.S. FDA and Health Canada, today announced that it will host an exclusive, invitation-only "SynCardia Total Artificial Heart Training Village" at Hous

TUCSON, Ariz., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE:PMI) ("Picard" or the "Company"), parent company of SynCardia Systems LLC, maker of the world's first total artificial heart approved by both the U.S. FDA and Health Canada, today announced that University of California, San Francisco (UCSF) Health has successfully performed its first heart transplant in a patient who had previously been supported with the SynCardia Total Artificial Heart, marking an important clinical milestone in the treatment of advanced biventricular heart failure. UCSF Health is the U.S. News & World Report 2025-2026 top-ranked hospital in California. UCSF announced in a press release yesterd

TUCSON, Ariz., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE:PMI) ("Picard" or the "Company"), parent company of SynCardia Systems LLC, maker of the world's first total artificial heart approved by both the U.S. FDA and Health Canada, today announced that Dr. Andre Simon, Vice President of Clinical Affairs will attend and present data on the fully implantable Emperor Total Artificial Heart (TAH) at the upcoming 19th EUMS (European Mechanical Circulatory Support Summit) & 11th International Course on Mechanical Circulatory Support (MCS) and New Technologies in Advanced Heart Failure (HF) congress, being held February 15th - 18th, 2026 in Barcelona, Spain. Details of the pres

8-K - Picard Medical, Inc. (0002030617) (Filer)

8-K - Picard Medical, Inc. (0002030617) (Filer)

8-K - Picard Medical, Inc. (0002030617) (Filer)

8-K - Picard Medical, Inc. (0002030617) (Filer)

8-K - Picard Medical, Inc. (0002030617) (Filer)

8-K - Picard Medical, Inc. (0002030617) (Filer)

8-K - Picard Medical, Inc. (0002030617) (Filer)

DEFR14A - Picard Medical, Inc. (0002030617) (Filer)

DEF 14A - Picard Medical, Inc. (0002030617) (Filer)

SCHEDULE 13G - Picard Medical, Inc. (0002030617) (Subject)

3 - Picard Medical, Inc. (0002030617) (Issuer)